ORGN is a leader in sustainable chemistry, engineering the next generation of bio-based polymers to replace fossil fuel-derived materials across high-growth industrial sectors.
ORGN represents a high-risk, high-reward opportunity to capitalize on the global shift toward sustainable materials and ESG-compliant supply chains. The company's proprietary technology offers a clear pathway to replace billions of dollars worth of petrochemical demand with carbon-negative alternatives, positioning it as a potential market disruptor if commercialization scales successfully.
The company faces severe financial headwinds characterized by a massive deficit in retained earnings ($-38.1M) and negative net profit trends over the last two years. Investors must weigh the ambitious sustainability mission against the reality of limited cash reserves and the potential for further dilution through equity financing to cover substantial operating deficits.
Origin Materials, Inc. (ORGN) is a pioneering sustainable materials company focused on manufacturing bio-based polymers and carbon-negative alternatives to traditional petrochemicals. The company primarily serves industries such as automotive, aerospace, and consumer goods, providing drop-in replacements for plastics and other essential materials derived from renewable feedstocks like agricultural waste.
Despite achieving gross profit of $31.3M, the company reported a net loss of $-83.7M, largely driven by heavy investments in research and development ($18.6M) and general administrative costs ($40.8M). The significant negative cash flow from operations suggests the business is still in a capital-intensive growth phase, relying on financing activities ($3.6M inflow) to sustain liquidity while scaling production capabilities.
The sustainable materials industry is experiencing rapid growth as global corporations face increasing pressure to meet Scope 3 emission targets and reduce their carbon footprints. Origin Materials operates in a niche but expanding market where traditional petrochemical supply chains are being challenged by bio-based alternatives, though scaling manufacturing remains a significant barrier to entry.
| Metric | 2023 | 2024 |
|---|---|---|
| Revenue | $28.8M | $31.3M |
| Cost of Revenue | $0 | $0 |
| Gross Profit | $28.8M | $31.3M |
| Operating Expenses | $83.7M | $116.1M |
| Operating Income | $-54.9M | $-84.9M |
| R&D | $21.4M | $18.6M |
| G&A | $35.4M | $40.8M |
| Stock-Based Comp | $9.4M | $10.1M |
| D&A | $3.4M | $10.7M |
| Depreciation | $3.3M | $10.7M |
| Other OpEx | $27.0M | $56.8M |
| Non-Operating Income | $77.6M | $1.8M |
| Interest Expense | $131.0K | — |
| Pre-Tax Income | $22.7M | $-83.0M |
| Income Tax | $-1.1M | $669.0K |
| Continuing Ops | $23.8M | $-83.7M |
| Discontinued Ops | $0 | $0 |
| Net Income | $23.8M | $-83.7M |
| Minority Interest | $0 | $0 |
| Net to Common | $23.8M | $-83.7M |
| Metric | 2023 | 2024 |
|---|---|---|
| Current Assets | $187.1M | $139.2M |
| Cash & Equivalents | $75.5M | $56.3M |
| Accounts Receivable | $16.1M | $19.2M |
| Inventory | $912.0K | $866.0K |
| Prepaid Expenses | $8.4M | $2.4M |
| Other Current Assets | $86.2M | $60.4M |
| Long-Term Assets | $274.7M | $238.9M |
| PP&E (Net) | $243.1M | $203.9M |
| Intangibles | $121.0K | $73.0K |
| Operating Leases | $4.5M | $3.7M |
| Other LT Assets | $27.0M | $31.1M |
| Total Assets | $461.8M | $378.0M |
| Current Liabilities | $12.9M | $12.5M |
| Accounts Payable | $1.9M | $2.9M |
| Current Leases | $367.0K | $323.0K |
| Other Current Liab | $2.9M | $6.5M |
| Long-Term Liabilities | $26.5M | $27.1M |
| LT Operating Leases | $4.2M | $3.9M |
| Other LT Liab | $22.3M | $23.3M |
| Total Liabilities | $39.3M | $39.7M |
| Shareholders' Equity | $422.5M | $338.4M |
| Paid-In Capital | $382.9M | $393.2M |
| Retained Earnings | $45.6M | $-38.1M |
| AOCI | $-5.9M | $-16.7M |
| Total L&E | $461.8M | $378.0M |
| Metric | 2023 | 2024 |
|---|---|---|
| Net Income (CFO) | $23.8M | $-83.7M |
| Non-Cash Adjustments | $-123.5M | $32.1M |
| Working Capital Changes | $39.4M | $737.0K |
| Cash from Operations | $-60.4M | $-50.8M |
| Capital Expenditures | $102.2M | $9.0M |
| Cash from Investing | $26.2M | $28.6M |
| Cash from Financing | $146.0K | $3.6M |
| FX Effect | $1.1M | $-480.0K |
| Net Change in Cash | $-32.8M | $-19.2M |
| Beginning Cash | $108.3M | $75.5M |
| Ending Cash | $75.5M | $56.3M |
The company's revenue streams are driven by its proprietary bio-based polymer technology platform, which targets key end-markets including automotive components, aerospace parts, and consumer goods packaging. Recent financials indicate a focus on scaling production capabilities to reduce reliance on marketable security purchases while managing high operating expenses related to research, development, and general administration.
1) Significant cash burn and negative operating cash flow ($-50.8M) raising concerns about liquidity and the ability to fund operations without external financing. 2) High dependency on non-operating income and substantial mark-to-market losses on marketable securities, which can distort earnings volatility. 3) Intense competition from established petrochemical giants and emerging biotech rivals in a capital-intensive manufacturing sector.
1) Proprietary biotechnology platform enabling the creation of carbon-negative materials that offer direct functional replacements for petrochemical products. 2) Strong intellectual property portfolio protecting its unique chemical synthesis pathways against industry competitors. 3) Strategic partnerships with major downstream manufacturers committed to sustainability goals, providing a pipeline for future commercialization.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.